Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets

[1]  N. Kohno,et al.  Clinical and molecular features of rapidly progressive chronic hypersensitivity pneumonitis , 2017, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[2]  Y. Obase,et al.  Association of elevated α-defensin levels with interstitial pneumonia in patients with systemic sclerosis , 2015, Respiratory Research.

[3]  S. Kudoh,et al.  All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. , 2015, Respiratory investigation.

[4]  N. Kohno,et al.  MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis , 2015, Respirology.

[5]  S. Kudoh,et al.  A prospective survey of idiopathic interstitial pneumonias in a web registry in Japan. , 2015, Respiratory investigation.

[6]  Ivana V. Yang,et al.  The MUC5B promoter polymorphism is associated with idiopathic pulmonary fibrosis in a Mexican cohort but is rare among Asian ancestries. , 2015, Chest.

[7]  M. Tomonaga,et al.  Elevated plasma α-defensins in patients with acute exacerbation of fibrotic interstitial pneumonia. , 2015, Respiratory medicine.

[8]  H. Nakagawa,et al.  Antibody-coupled monolithic silica microtips for highthroughput molecular profiling of circulating exosomes , 2014, Scientific Reports.

[9]  R. Sussman,et al.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[10]  Shandra L. Protzko,et al.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. , 2013, American journal of respiratory and critical care medicine.

[11]  A. Borczuk,et al.  Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis. , 2013, The European respiratory journal.

[12]  Yusuke Nakamura,et al.  Preapoptotic protease calpain-2 is frequently suppressed in adult T-cell leukemia. , 2013, Blood.

[13]  N. Kohno,et al.  Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. , 2012, Respiratory investigation.

[14]  N. Kohno,et al.  Krebs von den Lungen‐6 (KL‐6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer , 2011, International journal of cancer.

[15]  S. Sahn,et al.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials , 2011, The Lancet.

[16]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[17]  I. Rahman,et al.  Hemoglobin α and β are ubiquitous in the human lung, decline in idiopathic pulmonary fibrosis but not in COPD , 2010, Respiratory research.

[18]  D. Fairclough,et al.  Pirfenidone in idiopathic pulmonary fibrosis , 2010, European Respiratory Journal.

[19]  Bin Fang,et al.  A chemical and phosphoproteomic characterization of dasatinib action in lung cancer , 2010, Nature chemical biology.

[20]  G. Raghu,et al.  Pirfenidone in idiopathic pulmonary fibrosis , 2009, European Respiratory Journal.

[21]  S. Ohlmeier,et al.  Proteomic approaches for studying human parenchymal lung diseases , 2009, Expert review of proteomics.

[22]  Jin Woo Song,et al.  Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. , 2009, American journal of respiratory and critical care medicine.

[23]  C. D. Savci-Heijink,et al.  The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung. , 2009, The American journal of pathology.

[24]  E. Buchdunger,et al.  Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. , 2008, European journal of pharmacology.

[25]  Yusuke Nakamura,et al.  From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma , 2008, General thoracic and cardiovascular surgery.

[26]  N. Kohno,et al.  Immunohistochemical and immunoelectron microscopic studies of the localization of KL-6 and epithelial membrane antigen (EMA) in presumably normal pulmonary tissue and in interstitial pneumonia , 2007, Medical Molecular Morphology.

[27]  Y. Miyagi,et al.  Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. , 2007, Cancer research.

[28]  G. Laurent,et al.  Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? , 2007, European Respiratory Journal.

[29]  N. Kaminski,et al.  Accelerated Variant of Idiopathic Pulmonary Fibrosis: Clinical Behavior and Gene Expression Pattern , 2007, PloS one.

[30]  Susan Murray,et al.  Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? , 2007, American journal of respiratory and critical care medicine.

[31]  Yusuke Nakamura,et al.  Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. , 2006, International journal of oncology.

[32]  W. Vogel,et al.  Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis. , 2006, American journal of respiratory and critical care medicine.

[33]  M. Selman,et al.  Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. , 2006, Proceedings of the American Thoracic Society.

[34]  Naftali Kaminski,et al.  Gene expression profiling as a window into idiopathic pulmonary fibrosis pathogenesis: can we identify the right target genes? , 2006, Proceedings of the American Thoracic Society.

[35]  Naftali Kaminski,et al.  Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. , 2006, American journal of respiratory and critical care medicine.

[36]  Yusuke Nakamura,et al.  Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. , 2005, Cancer research.

[37]  M. Burdick,et al.  CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. , 2005, American journal of respiratory and critical care medicine.

[38]  Yusuke Nakamura,et al.  ADAM8 as a Novel Serological and Histochemical Marker for Lung Cancer , 2004, Clinical Cancer Research.

[39]  A. Nicholson,et al.  Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. , 2004, Chest.

[40]  N. Kohno,et al.  Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. , 2002, American journal of respiratory and critical care medicine.

[41]  Paul J. Friedman,et al.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors , 2002, American journal of respiratory and critical care medicine.

[42]  R. Strawderman,et al.  Histopathologic variability in usual and nonspecific interstitial pneumonias. , 2001, American journal of respiratory and critical care medicine.

[43]  A. Pardo,et al.  Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy , 2001, Annals of Internal Medicine.

[44]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Roderic D. M. Page,et al.  TreeView: an application to display phylogenetic trees on personal computers , 1996, Comput. Appl. Biosci..

[46]  N. Kohno,et al.  New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. , 1989, Chest.

[47]  N. Kohno,et al.  Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. , 1988, Japanese journal of clinical oncology.

[48]  O. J. Dunn.  Multiple Comparisons Using Rank Sums , 1964 .

[49]  A. Azuma,et al.  A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis , 2015 .

[50]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.

[51]  Ivana V. Yang,et al.  Gene expression profiling of familial and sporadic interstitial pneumonia. , 2007, American journal of respiratory and critical care medicine.

[52]  M. Selman,et al.  AMERICAN THORACIC SOCIETY; EUROPEAN RESPIRATORY SOCIETY; AMERICAN COLLEGE OF CHEST PHYSICIANS. IDIOPATHIC PULMONARY FIBROSIS: PREVAILING AND EVOLVING HYPOTHESES ABOUT ITS PATHOGENESIS AND IMPLICATIONS FOR THERAPY , 2001 .

[53]  T. Nishikawa,et al.  Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1. , 1998, The Journal of investigative dermatology.